PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

Peg Interferon Alpha 2b (Peg Intron)

4.5 micrograms/kg once a week

DRUG

Ara-C (cytosine arabinoside)

10 mg under the skin daily

Trial Locations (1)

The University of Texas M.D. Anderson Cancer Center, Houston